Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432561 | 0.81 | OPRM1 (0.59) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL1366600 | 0.78 | OPRM1 (0.53) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL13163462 | 0.78 | OPRM1 (0.36) | OPRM1 | |
| SCHEMBL31417097 | 0.78 | OPRM1 (0.34) | OPRM1 | |
| SCHEMBL3888335 | 0.78 | OPRM1 (0.53) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL1558872 | 0.78 | MAOB (0.36) | OPRM1NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL56575 | 0.77 | NPC1 (0.57) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL872608 | 0.77 | OPRM1 (0.56) | OPRM1CA12CA1CA2CA9 | |
| SCHEMBL31417072 | 0.77 | HSD11B1 (0.38) | OPRM1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14101119 | 0.77 | HSD11B1 (0.38) | OPRM1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084087-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| WO-2025042730-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2010-09-16 | — | — | US | disclosed |
| US-7514431-B2 | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514431-B2 | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7494986-B2 | Cycloalkylamine derivatives as NK-1/SSRI antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| EP-0655057-B1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS | UPJOHN CO (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5567722-A | DIURETICS | THE UPJOHN COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0655057-A1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS. | UPJOHN CO (US) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994004500-A1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS | THE UPJOHN COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234409-A1 | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity | CXCR3, CXCR1, CCR2 | OPRM1 1169/4885CA12 2548/4885CA1 1722/4885 |
| US-20250084087-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | OPRM1 386/4885CA12 4677/4885CA1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.